secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001689548-25-000116
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis gets FDA nod to simplify EMBRAVE3 study; relutrigine NDA on track for early 2026
--------------------------------------------------------------------------------

- FDA agreed to convert EMBRAVE3 from double-blind to single-arm baseline-controlled study, enrolling 30 patients (down from 40).
- Primary analysis will be change from baseline in countable motor seizures; all screening patients now assigned to elsunersen.
- EMBRAVE Part A (9 patients, 3:1 randomization) topline results expected in first half of 2026.
- FDA confirmed that Praxis can file a New Drug Application for relutrigine in SCN2A and SCN8A DEEs in early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/0001689548-25-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/prax-20251209.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer